MARKET

SYRS

SYRS

Syros Pharmaceut
NASDAQ
3.950
-0.030
-0.75%
After Hours: 3.950 0 0.00% 16:00 09/29 EDT
OPEN
3.940
PREV CLOSE
3.980
HIGH
3.960
LOW
3.858
VOLUME
41.05K
TURNOVER
0
52 WEEK HIGH
6.95
52 WEEK LOW
2.420
MARKET CAP
81.80M
P/E (TTM)
-0.7361
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at SYRS last week (0918-0922)?
Weekly Report · 4d ago
Weekly Report: what happened at SYRS last week (0911-0915)?
Weekly Report · 09/18 09:01
Syros Pharmaceut: Statement of changes in beneficial ownership of securities
Press release · 09/14 21:15
Weekly Report: what happened at SYRS last week (0904-0908)?
Weekly Report · 09/11 09:01
Weekly Report: what happened at SYRS last week (0828-0901)?
Weekly Report · 09/04 09:09
Weekly Report: what happened at SYRS last week (0821-0825)?
Weekly Report · 08/28 09:01
Weekly Report: what happened at SYRS last week (0814-0818)?
Weekly Report · 08/21 11:00
Novo Integrated, Aeon top healthcare gainers; Impel, Jupiter Wellness among losers
Seeking Alpha · 08/16 14:08
More
About SYRS
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. Its lead product candidates include Tamibarotene and SY-2101. Its Tamibarotene, is a selective retinoic acid receptor alpha (RARα), agonist RARA-positive patients with higher-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML). Its SY-2101, is an oral form of arsenic trioxide (ATO) being developed for the treatment of acute promyelocytic leukemia (APL). The Company’s product candidate also includes SY-5609, which is a selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7) which is being developed for patients with select solid tumors and in combination with gemcitabine and with gemcitabine plus nab-paclitaxel in patients with metastatic pancreatic cancer. It is also focused on the development for the treatment of multiple preclinical programs in oncology.

Webull offers kinds of Syros Pharmaceuticals Inc stock information, including NASDAQ:SYRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYRS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SYRS stock methods without spending real money on the virtual paper trading platform.